Generate:Biomedicines announced a multi-target collaboration with Novartis to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s proprietary generative AI...
Multi-year collaboration will enable development of complex, cutting-edge cell therapies and armoring technologies for solid tumor targets
Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced...
Generate:Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, announced that it has raised $273 million in Series C financing. This financing...